AIM Vaccine Co., Ltd. (HKG:6660)
Hong Kong
· Delayed Price · Currency is HKD 3.090
+0.090 (3.00%)
Mar 10, 2026, 3:37 PM HKT
AIM Vaccine Revenue
AIM Vaccine had revenue of 514.66M CNY in the half year ending June 30, 2025, a decrease of -4.78%. This brings the company's revenue in the last twelve months to 1.26B, up 6.62% year-over-year. In the year 2024, AIM Vaccine had annual revenue of 1.29B with 8.22% growth.
Revenue (ttm)
1.26B CNY
Revenue Growth
+6.62%
P/S Ratio
2.66
Revenue / Employee
845.62K CNY
Employees
1,493
Market Cap
3.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Qyuns Therapeutics | 351.04M |
| TYK Medicines | 117.25K |
| Medtide | 546.29M |
| BioDlink International Company | 1.17B |
| Mirxes Holding Company | 166.32M |
| Shandong Boan Biotechnology | 829.27M |
| Viva Biotech Holdings | 2.01B |
| Jacobio Pharmaceuticals Group | 220.66M |